Pasithea Therapeutics - Warrants (11/08/2026) Return on Equity

Pasithea Therapeutics - Warrants (11/08/2026) (KTTAW) currently reports a ROE of -63.4%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Pasithea Therapeutics - Warrants (11/08/2026)'s ROE history and peer comparisons.

Pasithea Therapeutics - Warrants (11/08/2026)'s ROE of -63.4% is lower than the Healthcare sector average of 21.67%. That is roughly 392.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Pasithea Therapeutics - Warrants (11/08/2026)'s current -63.4% should be judged against Healthcare norms (sector average: 21.67%) and against KTTAW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -63.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Pasithea Therapeutics - Warrants (11/08/2026), and consider following KTTAW for alerts when major investors trade the stock.

Pasithea Therapeutics - Warrants (11/08/2026) is classified in the Healthcare sector. On ROE, it currently shows -63.4% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KTTAW with unrelated industries.